Evolution of pancreatic function during the first year in infants with cystic fibrosis
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
O'Sullivan, Brian P.Baker, Dawn
Leung, Katherine G.
Reed, George W.
Baker, Susan S.
Borowitz, Drucy
UMass Chan Affiliations
Department of PediatricsDepartment of Medicine, Division of Preventive and Behavorial Medicine
Document Type
Journal ArticlePublication Date
2013-04-01Keywords
Cohort StudiesCystic Fibrosis
Docosahexaenoic Acids
Exocrine Pancreatic Insufficiency
Feces
Female
Genotype
Homozygote
Humans
Infant
Infant, Newborn
Longitudinal Studies
Male
Neonatal Screening
Pancreatic Elastase
Pancreatic Function Tests
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Pediatrics
Respiratory Tract Diseases
Metadata
Show full item recordAbstract
OBJECTIVE: To describe pancreatic function during the first year of life in infants diagnosed with cystic fibrosis (CF) using serial fecal elastase measurements. STUDY DESIGN: This was a longitudinal study of 82 infants diagnosed with CF through newborn screening. Monthly stool samples were sent to a central laboratory for fecal elastase measurements. RESULTS: A total of 61 infants had an initial stool sample obtained at age 9 months. Twenty-six of 29 infants with a fecal elastase value /g at study entry had a fecal elastase value /g (the accepted cutoff value for pancreatic insufficiency) on all measurements during the year; all 29 had a value /g at the end of the study. Of the 48 infants with initial fecal elastase value /g, 13 had at least 1 fecal elastase value >200 mug/g but had a final stool fecal elastase value /g; however, 4 infants with an initial fecal elastase value /g ended the year with a value >200 mug/g. Eleven of 13 infants with an initial fecal elastase value of >200 mug/g still had a value >200 mug/g at the end of the first year. CONCLUSION: Infants with CF exhibit variability in fecal elastase values during the first year. Infants with a fecal elastase level of 50-200 mug/g at diagnosis should be treated with pancreatic enzyme replacement therapy, but fecal elastase should be remeasured at age 1 year to ensure that those with a falsely low value do not continue to receive pancreatic enzyme replacement therapy unnecessarily. Those with a fecal elastase value >200 mug/g initially can become pancreatic insufficient with time.Source
J Pediatr. 2013 Apr;162(4):808-812.e1. doi: 10.1016/j.jpeds.2012.10.008. Link to article on publisher's siteDOI
10.1016/j.jpeds.2012.10.008Permanent Link to this Item
http://hdl.handle.net/20.500.14038/28931PubMed ID
23245194Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.jpeds.2012.10.008